Similarly, our findings reveal miR-32-5p as a novel regulator of c-MYC-driven proliferation in HER2-negative breast cancer, further supporting the potential of targeting non-canonical pathways in aggressive subtypes and can be further Clinical Implications[54]. This evidence concerns the gene ERBB2 and breast carcinoma.